	US 11,747,335 B2
	Compositions and methods for assaying platelet reactivity and treatment selection
David Schneider, Burlington, VT (US)
Assigned to University of Vermont And State Agriculture College, Burlington, VT (US)
Filed by University of Vermont And State Agriculture College, Burlington, VT (US)
Filed on Oct. 30, 2019, as Appl. No. 16/668,397.
Application 16/668,397 is a division of application No. 14/403,337, granted, now 10,502,737, previously published as PCT/US2013/042540, filed on May 23, 2013.
Claims priority of provisional application 61/651,779, filed on May 25, 2012.
Prior Publication US 2020/0166508 A1, May 28, 2020
Int. Cl. G01N 33/53 (2006.01); G01N 33/569 (2006.01); G01N 33/86 (2006.01); G01N 33/68 (2006.01); A61K 31/4365 (2006.01); A61K 31/443 (2006.01); A61K 31/519 (2006.01)

CPC G01N 33/56966 (2013.01) [A61K 31/4365 (2013.01); A61K 31/443 (2013.01); A61K 31/519 (2013.01); G01N 33/6854 (2013.01); G01N 33/86 (2013.01); G01N 2333/70535 (2013.01); G01N 2800/222 (2013.01); G01N 2800/226 (2013.01); G01N 2800/52 (2013.01)]

25 Claims

1. A method of treating a selected subject at risk of thrombosis with an anti-thrombotic therapy, the method comprising:

administering an anti-thrombotic agent that is an Adenosine diphosphate (ADP) receptor antagonist and/or a Protease-activated receptor (PAR) antagonist to the selected subject, wherein the subject is selected by detecting a level of copies of FcγRlla per platelet from the subject and comparing the level of copies of FcγRlla per platelet from the subject against a level of copies of FcγRlla per platelet from a disease-free individual, wherein a level increased by at least about 1.5-5 fold of FcγRlla per platelet identifies the subject as at risk of thrombosis and in need of anti-thrombotic therapy.